Submit Manuscript  

Article Details

Risk Mortality, prevalence, and possible therapeutics to treat diabetic patients infected with nCOVID-19


Sumel Ashique and Navjot K Sandhu*  


The whole world is facing the current potential life-threatening virus nCOVID-19, the most severe health crisis in the modern era. The World Health Organization (WHO) has announced the nCOVID-19 as a pandemic in global concern. People with diabetes are not more likely to get nCOVID-19 than the general population. However, nCOVID-19 can cause more severe symptoms and complications in some people living with Diabetes. Older individuals and individuals with previous ailments, (such as diabetes, coronary illness, and asthma) have all the earmarks of being more susceptible to nCOVID-19 infection. People having diabetic condition becomes more challenging to treat against nCOVID-19 due to firstly, the insusceptible systemic undermined, making it harder to battle the infection and likely prompting a more drawn out recuperation period and secondly the infection may flourish in a situation of raised blood glucose. Various therapeutic (anti-diabetic drugs) approaches are available to treat diabetic patients from having nCOVID-19. This review mainly focused on the effect of this virus on type diabetic patients, mortality rate, the mechanism involved, associated complications, and the role of vitamin D, Zn, therapeutics, and prevention procedure.


nCOVID-19, diabetes and nCOVID-19, risk-mortality, health problems, therapeutics.


Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, Department of Quality Assurance and Pharmaceutical Analysis, ISF College of Pharmacy, Moga, Punjab

Full Text Inquiry